AVN-211 (CD-008-0173) is a
drug which acts as a highly selective
5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of
schizophrenia
Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major symptoms include hallucinations (typically hearing voices), delusions, and disorganized thinking. Other symptoms include social wit ...
.
In early 2011, it successfully completed
phase IIa clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...
s,
with benefits on
positive symptoms and some
procognitive effects observed,
and in mid 2013,
phase IIb
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...
clinical trials for schizophrenia began.
Avineuro Pharmaceuticals has also expressed intention to start clinical trials of AVN-211 for
Alzheimer's disease in 2015.
See also
*
List of investigational antipsychotics
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names ...
*
AVN-101
AVN-101, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders. As of November 2013, it is i ...
References
External links
Pipeline - Avineuro Pharmaceuticals, Inc.
5-HT6 antagonists
Antipsychotics
Experimental drugs
{{Nervous-system-drug-stub